David Ricks; Chairman of the Board, President, Chief Executive Officer; Eli Lilly and Co Lucas Montarce; Executive Vice President and Chief Financial Officer; Eli Lilly and Co Daniel Skovronsky; Chief ...

David Ricks; Chairman of the Board, President, Chief Executive Officer; Eli Lilly and Co Lucas Montarce; Executive Vice President and Chief Financial Officer; Eli Lilly and Co Daniel Skovronsky ...

Lucas Montarce-- Executive Vice President ... in everything about Eli Lilly and Company. If you've got follow-up questions or things we didn't cover in enough detail today in the Q&A, please ...

Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I would now like to turn the conference over to your host, Mike Czapar, senior ...

CFO Lucas Montarce reported a gross margin increase ... were acknowledged but framed as opportunities to showcase product differentiation. Eli Lilly ended 2024 on a strong note, with 45% revenue ...

Good morning, thank you for joining us for Eli Lilly and Company's Q4 2024 ... Chief Scientific Officer and President of Lilly Immunology; Lucas Montarce, Chief Financial Officer; Anne White ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.